Back to Search Start Over

Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Authors :
Philip A. Read
Simon Bond
Liam Ring
Stephen P. Hoole
David P. Dutka
Anna C. Kydd
Liam M. McCormick
Source :
Circulation: Cardiovascular Imaging. 7:274-281
Publication Year :
2014
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2014.

Abstract

Background— The incretin hormone, glucagon-like peptide-1, promotes myocardial glucose uptake and may improve myocardial tolerance to ischemia. Endogenous glucagon-like peptide-1 (7–36) is augmented by pharmacological inhibition of dipeptidyl peptidase-4. We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protected against ischemic left ventricular dysfunction during dobutamine stress in patients with type 2 diabetes mellitus and coronary artery disease. Methods and Results— A total of 19 patients with type 2 diabetes mellitus underwent dobutamine stress echocardiography with tissue Doppler imaging on 2 separate occasions: the first (control) while receiving oral hypoglycemic agents, and the second after the addition of sitagliptin (100 mg once daily) for ≈4 weeks. Sitagliptin increased plasma glucagon-like peptide-1 (7–36) levels and, at peak stress, enhanced both global (ejection fraction, 70.5±7.0 versus 65.7±8.0%; P P =0.01) and regional left ventricular function, assessed by peak systolic velocity and strain rate in 12 paired, nonapical segments. This was predominantly because of a cardioprotective effect on ischemic segments (strain rate in ischemic segments, −2.27±0.65 versus −1.98±0.58 s −1 ; P =0.001), whereas no effect was seen in nonischemic segments (−2.19±0.48 versus −2.18±0.54 s −1 ; P =0.87). At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postischemic stunning seen in the control scan. Conclusions— The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning. Clinical Trial Registration— URL: http://www.isrctn.org . Unique identifier ISRCTN61646154.

Details

ISSN :
19420080 and 19419651
Volume :
7
Database :
OpenAIRE
Journal :
Circulation: Cardiovascular Imaging
Accession number :
edsair.doi.dedup.....5f39e195893160bf35a0c89477df41b0
Full Text :
https://doi.org/10.1161/circimaging.113.000785